Nabriva gets first approval in novel antibiotic class
Nabriva plans to launch its first approved antibiotic, Xenleta lefamulin, in mid-September to treat community-acquired bacterial pneumonia, and the company has taken steps to facilitate Xenleta's adoption through negotiations with healthcare providers, payers and pharmacies.
FDA approved on Monday a pair of NDAs from Nabriva Therapeutics plc (NASDAQ:NBRV) for IV and oral Xenleta, which represent a new antibacterial class that blocks protein synthesis by binding the peptidyl transferase center of bacterial ribosomes. On a conference call Monday, CEO Ted Schroeder noted it is the first antibiotic from a new class approved for community-acquired bacterial pneumonia in almost 20 years...
BCIQ Company Profiles